Neuraly

Neuraly is a globally renowned clinical-stage biopharmaceutical company founded by scientists and physicians in the field of neurodegenerative diseases. Its mission is to transform scientific discoveries in neurology into revolutionary new drugs that can fundamentally change, improve, and extend the lives of individuals suffering from catastrophic consequences of diseases such as Parkinson's disease, Alzheimer's disease, and other neurodegenerative conditions. Currently, even with the most advanced treatments available, these diseases unfortunately result in outcomes where many new drugs under development can only temporarily alleviate symptoms. For today’s patients, these diseases severely impact their quality of life and life expectancy. Families and entire communities find the joy of longevity shattered in a fleeting moment. Neuraly was established to develop new drugs that could potentially transform our expectations for successfully treating progressive diseases like Alzheimer’s and Parkinson’s. This is our benchmark. Neuraly is developing treatments for neurodegenerative diseases that offer new hope, address novel pathways, leverage the innovative achievements of its founders, and provide potentially life-changing medications.